ICICI Prudential Mutual Fund adds ₹150 crore of Sagility at ₹42.75 as the promoter sells 12%: September-quarter profit up 13%, but is a 19-times P/E a buy?
ICICI Prudential Mutual Fund bought about ₹150 crore of Sagility shares at ₹42.75 on 30 October 2026, adding to a holding it already had. It was one of many buyers of a 12% stake sold by Sagility's promoter, Sagility B.V., in a ₹2,395 crore block. Sagility's September 2026 quarter revenue rose 22.5% and profit rose 13%, and management raised its margin guidance. Yet the stock fell 5.8% on the day, to ₹42.08. This article looks at who sold, who bought, and what the numbers say.
The block trade comes from exchange bulk-deal data (NSE) and news reports. The reason for the promoter's sale has not been published. The data does not say which ICICI Prudential schemes bought.
Sagility Limited (NSE: SAGILITY, mainboard, not an SME stock) - Share price: ₹42.08 (close on 30 October 2026, down 5.78%) - Market cap: about ₹19,700 crore - P/E: about 19.2 times the last twelve months' profit, and about 14.8 times expected profit - Peer comparison: Firstsource Solutions, a listed rival, trades at about 28 times last twelve months' profit and 20 times expected profit - Price against past prices: 40% above the ₹30 IPO price of November 2024, and 1.6% below the ₹42.75 that the fund paid
What happened in the block trade
On 30 October 2026, the promoter Sagility B.V. sold about 56 crore shares, or 11.96% of the company, at an average ₹42.76. That is about ₹2,395 crore. Earlier reports had said the plan was about ₹2,377 crore, with a floor price of ₹42.45. News reports say the promoter agreed to a 365-day lock-up on the shares it keeps. I did not see the agreement itself.
Before the sale, Sagility B.V. held 50.95% (September 2026 shareholding pattern). After it, my own arithmetic puts the promoter near 39%. That is not a reported figure. This was at least the fourth sale: the promoter sold about 15% in the November 2024 IPO, launched another share sale in May 2025 and sold about 16.4% in November 2025. Sales like these raise the share held by the public, which helps the company meet the stock exchange rule that at least 25% of shares must be public. Sagility itself receives no money from them: they pass existing shares from the promoter to new owners, and the IPO too was entirely such a sale.
Exchange bulk-deal data names the buyers who took more than 0.5% of the company each:
Buyer Shares Value (at about ₹42.75) --------- BNP Paribas Financial Markets 5,61,85,380 ₹240 crore Societe Generale 4,75,06,626 ₹203 crore Ghisallo Master Fund 4,45,64,304 ₹190 crore Icici Prudential Mutual Fund 3,50,87,719 ₹150 crore ICICI Prudential Life Insurance 3,25,88,537 ₹139 crore Goldman Sachs Funds (India Equity Portfolio), bought at ₹42.62 2,72,67,148 ₹116 crore
These six took about 24 crore shares, which is 43% of the block. The other 57% went to buyers that the exchange data does not name. ICICI Prudential Mutual Fund's ₹150 crore is about 0.75% of Sagility. The fund and ICICI Prudential Life Insurance are separate companies that share a brand.
The fund already held Sagility before this: the exchange tracker marks it as an add-on, and a news report names ICICI Prudential among the buyers when the promoter sold about 16.4% in November 2025. I could not find the fund's holding at September 2026, so I cannot say how big the position is now.
A big fund buying a promoter's block is not a signal by itself The promoter chose the day, the price and the size. A block sold at a small discount finds buyers by design. The stock closed 1.6% below the block price. Your own research on the business matters more than who bought.
The business
Sagility provides outsourced technology and operations services to US health insurers and healthcare providers. It handles work such as claims, member services and payment checks. The company was incorporated in 2021 (one report says July 2021), though the healthcare services business it holds is older. It listed on the NSE and BSE on 12 November 2024. The IPO price was ₹30, and the shares listed at ₹31.06. One report names the private-equity firm EQT as the backer behind the promoter entity. I could not confirm that from the IPO documents.
The company's Q2 FY27 results report 51,486 employees in five countries. Its clients are US healthcare organisations, so rupee and dollar moves matter to its results.
Financial trend
Year to March Revenue (₹ crore) Net profit (₹ crore) Cash from operations (₹ crore) ------------ FY23 4,218 144 857 FY24 4,754 228 973 FY25 5,570 539 1,214 FY26 7,193 925 1,203 12 months to September 2026 7,991 1,026 1,279
Revenue grew about 1.9 times from FY23 to the last twelve months. Profit grew about seven times, partly because lower debt and rising margins carried more of each rupee of revenue through to profit. I did not split the rise year by year, and acquisitions, depreciation, tax and one-off items also play a part. The FY22 figures cover only part of a year, so I left them out.
The September 2026 quarter, against a year ago:
Measure September 2026 quarter September 2025 quarter Change ------------ Revenue ₹2,032 crore About ₹1,659 crore +22.5% (12.2% at constant exchange rates) Adjusted EBITDA ₹535 crore, a 26.3% margin — +23.0% Net profit (reported) ₹284 crore About ₹251 crore +13.3% Net profit (adjusted by the company) ₹325 crore — +8.1% Reported EBITDA ₹525 crore — +11.0%
The year-ago figures are worked back from the reported growth rates. Management cites favourable currency moves as one reason for the margin gain. Growth at constant exchange rates was about half the headline rate. Note that profit after the company's own adjustments grew only 8.1%, slower than the 13.3% reported profit, and reported EBITDA (₹525 crore) grew 11.0%, slower than adjusted EBITDA (23.0%).
Cash, debt and receivables
- Profit turns into cash. Cash from operations was ₹1,279 crore in the last twelve months, about 1.25 times net profit. Part of the gap is non-cash charges such as amortisation. Free cash flow, which is cash from operations minus about ₹228 crore of capital spending, was about ₹1,051 crore (my calculation). - Debt is falling. Total debt on the data site fell from ₹2,532 crore in March 2024 to ₹902 crore in September 2026. That total includes about ₹476 crore of lease liabilities. Cash and bank balances were about ₹607 crore, plus about ₹399 crore of short-term investments. - Receivables are large. Trade receivables (money customers owe) were ₹1,775 crore in September 2026. That is about 22% of the last twelve months' revenue, or about 81 days of sales (my calculation, not a figure the company reports). It was about 94 days at March 2026 and 92 days at March 2024. All the work is for US healthcare clients, so a delay from one big client matters. I took these from a data site and have not read the notes in the annual report. - Goodwill is half of all assets. Goodwill of ₹6,609 crore is 51% of total assets of ₹12,858 crore. Goodwill is what remains of the price paid for past acquisitions after the identifiable assets are counted, so a write-down would hit profit and equity if those businesses disappoint. Return on equity is about 10.7%.
How Sagility is valued next to Firstsource
Measure Sagility Firstsource Solutions --------- Share price, 30 October 2026 ₹42.08 ₹288 Market cap About ₹19,700 crore About ₹20,265 crore P/E, last 12 months 19.2 28.0 P/E, expected 14.8 20.0 EV/EBITDA 10.2 15.5 Return on equity 10.7% 15.7% Revenue, last 12 months ₹7,991 crore ₹10,576 crore Net profit, last 12 months ₹1,026 crore ₹724 crore
Sagility earns more profit than Firstsource on less revenue and trades at a lower multiple. Firstsource has a higher return on equity. Sagility's lower return reflects its large goodwill base. The two do not compete head to head: Sagility serves only US healthcare, while Firstsource has a wider client list. The market may give Sagility a lower multiple because it depends on one customer sector and one currency.
Management guidance
These are management's own statements from the Q2 FY27 results and earnings call on 22 and 29 October 2026. They are goals, not facts.
- FY27 adjusted EBITDA margin of 25% to 26%, raised from 24% to 25% - Low double-digit organic revenue growth at constant exchange rates for FY27, unchanged. Revenue from the yearly open-enrolment season is expected to be slightly lower than last year - The acquisition of Chirok Health, announced on 21 October 2026: about US$13 million of revenue in the 12 months to September 2026, a 35.8% adjusted EBITDA margin and 115% net revenue retention. The deal value and funding were not disclosed in the filings I read - 28 new client groups added in the first half of FY27 - An interim dividend of ₹0.15 a share, with a record date of 30 October 2026
I could not read older calls, so I cannot say whether past guidance was met.
Who runs it
- Ramesh Gopalan, managing director and group CEO, per the company's leadership page. - Sarvabhouman Doraiswamy Srinivasan, group chief financial officer, per the same page. - Hari Gopalakrishnan was re-appointed as a director by rotation at the annual meeting on 20 August 2026. - Chief growth officer Sohail Djariri resigned in November 2025, and Chris Shiffert replaced him in December 2025.
I did not find the ages, past careers or any related-party dealings. Check the annual report.
Risks and red flags
- Management changes with no details. The NSE list shows a "change in management" filing on 1 October 2026 and a resignation of a director or senior manager dated 31 October 2026, both with no name or reason. I did not read the filings. The 31 October one came a day after the block, so it is worth reading before you buy. - More promoter selling. The promoter has sold at least four times in two years and still holds about 39%, locked up for 365 days. After that, more supply is possible. - One customer sector. All revenue comes from US healthcare, which depends on US insurer budgets and rules. - Currency. Constant-currency growth was 12.2%, about half the 22.5% reported. A stronger rupee would reduce reported growth. - Goodwill and acquisitions. Chirok's price and funding are not disclosed. - Receivables. About 81 days of sales are still unpaid.
Price context
The stock closed at ₹42.08 on 30 October 2026, 1.6% below the block price of ₹42.76 (₹42.75 for the fund). The IPO price was ₹30. I did not find the 52-week range. Two brokerages published targets after the results: Motilal Oswal at ₹57 (Buy) and PL at ₹60 (Buy). That is 35% to 43% above the price. A target price is the broker's opinion, not a promise.
What to check before you buy
- Read the 31 October 2026 resignation filing and the 1 October management change. - Look for the September 2026 shareholding pattern, due in the coming weeks. It will show the fund's new holding and the promoter's holding. - Does the margin stay in the 25% to 26% range for a full year? - Do receivable days stay near 80?
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://www.whalesbook.com/news/English/sebiexchange/Sagility-Promoter-Sells-12percent-Stake-For-indian-rupee2395-Crore/6ae4d7044fc30694db54cb46 - https://www.inkl.com/news/sagility-block-deal-promoter-sagility-bv-likely-to-sell-12-stake-for-rs-2-377-crore - Exchange (NSE) bulk-deal data for SAGILITY, 30 October 2026 - https://www.investywise.com/sagility-ltd-q2-h1-fy27-financial-results-announcement/ - https://www.investywise.com/sagility-q2-fy27-investor-presentation/ - https://nsearchives.nseindia.com/corporate/SAGILITY22102026184424IntimationPressReleaseSigned.pdf - https://www.freepressjournal.in/amp/business/sagility-ipo-debuts-on-nse-with-353-premium-over-issue-price-of-30-a-piece - https://www.outlookbusiness.com/markets/sagility-india-eyes-rs-2107-crore-via-ipo-sets-price-band-at-rs-28-30-share - https://www.angelone.in/news/market-updates/sagility-share-price-in-focus-promoter-offloads-16-4-stake-51-holding-retained-after-sale - https://stockanalysis.com/quote/nse/SAGILITY/statistics/ - https://stockanalysis.com/quote/nse/SAGILITY/financials/ - https://stockanalysis.com/quote/nse/SAGILITY/financials/cash-flow-statement/ - https://stockanalysis.com/quote/nse/SAGILITY/financials/balance-sheet/ - https://stockanalysis.com/quote/nse/FSL/statistics/ - https://sagilityhealth.com/?p=403 - Sagility recent filings list on NSE (announcements for SAGILITY)